TIM-3 expression in breast cancer
Author:
Affiliation:
1. Genetic Pathology Evaluation Centre, University of British Columbia , Vancouver, Canada
2. Pathology and Laboratory Medicine Department, University of British Columbia , Vancouver, Canada
3. British Columbia Cancer Agency , Vancouver, Canada
Funder
Canadian Cancer Society
Fonds de la recherche en sante du Quebec
Publisher
Informa UK Limited
Subject
Oncology,Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1502128
Reference50 articles.
1. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
2. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
3. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
4. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
5. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09
2. Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer;Surgical Oncology;2024-02
3. Gene expression profile of immune-check point in response to Trastuzumab therapy in patients with HER-2 positive breast cancer;Wiadomości Lekarskie;2024
4. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors;Cancer Immunology, Immunotherapy;2023-08-11
5. Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival;Frontiers in Oncology;2023-03-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3